NCT06184750 2026-03-19
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT01272037 2026-03-18
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05941520 2026-03-18
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07478016 2026-03-17
EXIST
Thomas Jefferson University
Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT03909282 2026-03-12
NORDIS
Stanford University
Phase NA Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06982313 2026-03-11
Babytam long
Ente Ospedaliero Ospedali Galliera
Completed
NCT01349322 2026-03-05
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
Radiation Therapy Oncology Group
Phase 3 Active not recruiting
NCT03077841 2026-03-05
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
M.D. Anderson Cancer Center
Phase 2/3 Suspended
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT06617455 2026-03-02
VEnT
University of Michigan Rogel Cancer Center
Phase 2 Terminated